Clinical Trial Update: Cutting Edge Imaging With PET-FAPI for Earlier Pancreatic Cancer Diagnosis (INDIGO-FAPI) [Phase 2]

View source ↗

Summary

INDIGO-FAPI is a Phase 2 clinical trial investigating PET-FAPI imaging for earlier detection of pancreatic ductal adenocarcinoma, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• PET-FAPI imaging agent (Fibroblast Activation Protein Inhibitor (FAPI) imaging tracer)

Snippet

Sponsor: Institut Curie | Conditions: Pancreatic Ductal Adenocarcinoma (PDAC) | Phase 2 | Status: RECRUITING